相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- UVA Health's Rachelle Crescenzi, PhD, received a $6.5 million NIH grant to develop SALT MRI, a non-invasive imaging approach for lymphedema and lipedema. - Lymphedema affects over 10 million Americans and up to 250 million people worldwide, yet patients often face misdiagnosis or delayed treatment due to limited diagnostic tools. - SALT MRI measures sodium, adipose tissue, and lymphatic fluids, with early findings showing tissue sodium increases with disease severity and decreases after physical therapy. - The seven-year project aims to establish a center for lymphatic disease research at UVA and develop objective diagnostic exams for earlier detection and personalized treatment.
- UVA researchers analyzed 352 over-the-counter probiotic products from major U.S. pharmacy chains and found only 36 unique bacterial species, with no consistency in formulations linked to health claims. - The team developed HaPaPro, a collection of over 1,000 computer models of bacterial metabolism, to rationally design microbiome-targeted therapies. - Using HaPaPro, researchers successfully identified microbes with potential to prevent bacterial vaginosis, demonstrating the platform's therapeutic promise. - Findings published in Nature Microbiology highlight how computational modeling could lead to evidence-based probiotic products that deliver on their marketed health promises.
- Researchers at University of Virginia and University of Michigan developed a humanized monoclonal antibody targeting citrullinated histone H3 to combat sepsis, which kills approximately 11 million people worldwide annually. - Initial mouse studies demonstrate the antibody can prevent cytokine storms and restore macrophage function without unwanted immune suppression, showing potential for treating ARDS and autoimmune disorders. - The team received $800,000 from Virginia Catalyst to launch clinical trials, with the antibody engineered for clinical application alongside a diagnostic platform called PEdELISA. - The research identified molecular mechanisms in macrophages that drive sepsis-related inflammatory feedback loops, which the antibody successfully interrupts.
- Recent research indicates that over half of women aged 30-35 already experience moderate to severe perimenopause symptoms, yet most wait decades before seeking treatment. - A survey by Ohio State University found that 61% of women incorrectly believe menopause symptoms typically begin in their 40s, when most actually start experiencing them in their early 50s. - Healthcare experts emphasize that diet, exercise, and early medical consultation can significantly improve management of menopause symptoms and long-term health outcomes.
- The SCORPIO-PEP international trial found that ensitrelvir reduced COVID-19 infection risk by 67% in household contacts when administered within 72 hours of exposure. - Among high-risk participants with at least one risk factor for severe disease, the drug demonstrated even greater efficacy with a 76% reduction in infection risk. - Already approved in Japan for treating mild to moderate COVID-19, ensitrelvir could become an important preventive option for vulnerable populations if it receives FDA approval.
- Myelofibrosis patients face significant symptom burden that requires treatment intervention, with JAK inhibitors being the primary therapeutic option currently available. - Common adverse events from JAK inhibitors include severe thrombocytopenia, anemia, and gastrointestinal issues, often necessitating careful dose management. - Treatment challenges often force physicians to switch medications or drug classes when dose adjustments fail to maintain disease control while managing side effects.
- Real-world data confirms adding bevacizumab to first-line chemotherapy significantly extends time to next treatment in high-risk epithelial ovarian cancer patients from 11.7 to 13.6 months. - The study, published in Cancer, found a trend toward improved overall survival (31.1 vs 27.4 months) when bevacizumab was added to chemotherapy in patients with stage IV disease or stage III with visible residual disease. - Researchers analyzed 1,752 patients with stage III/IV epithelial ovarian cancer, concluding bevacizumab's benefits are specifically limited to those with defined high-risk prognostic factors.
- The FDA has approved Insightec's Exablate Neuro focused ultrasound system for treating advanced Parkinson's disease patients with mobility, rigidity, or dyskinesia symptoms through incisionless pallidotomy. - The treatment uses focused ultrasound waves to precisely target and ablate the globus pallidus without requiring brain implants or surgical incisions, reducing infection risk compared to invasive surgery. - This approval expands the device's indications beyond essential tremor and tremor-dominant Parkinson's disease, with 37 medical centers in the US currently using the technology. - Parkinson's disease affects an estimated one million patients in the United States, with the new approval providing a less invasive surgical option when medications are not well tolerated.
